A 42-year-old female patient suffered refractory insomnia. A variety of drugs including anti-anxiety, antidepressants, antipsychotics and repetitive transcranial magnetic stimulation (rTMS) have been applied in the treatment with no significant effect, whereas modified electroconvulsive therapy (MECT) can significantly improve the patient's sleep.
Introduction
Based on the Diagnostic and Statistical Manual of Mental Disorders, 4 th Edition,
Text revision (DSM-IV-TR), the diagnosis of insomnia is defined by a duration of at least 1 month and by symptoms that do not occur exclusively during the course of another sleep disorder, mental disorder, or medical disorder or result from use of substances or medications. The resistant or refractory insomnia can be defined if insomnia treatment with three different treatment options is unsuccessful. The traditional treatment of insomnia includes the use of benzodiazepines and non-benzodiazepine hypnotics [1] . Newly developed compounds such as GABA receptor subtype-selective compounds (S)-3-(aminomethyl)-5-methylhexanoic acid (Pregabalin) may overcome the side effects and the risk of drug dependence of classical benzodiazepine [2] . Melatonin, a physiological hormone involved in sleep timing, is currently used exogenously in the treatment of primary and secondary sleep disorders [3] [4] . Beyond drug treatment, clinicians started to explore other effective therapeu-tic way including physical stimulation, for example, the modified electroconvulsive therapy (MECT) [5] . MECT is a technically improved electric shock treatment, which is done under general anesthesia and muscle completely relaxed, while monitoring multiple body function parameters including blood pressure, Electroencephalography (EEG), pulse oxygen saturation and respiration.
The MECT has been clinically proven to be a relatively safe physical therapy in psychiatric treatments with fewer complications [6] [7] . Because of its curative effect and relative safety, MECT is widely used in clinical treatments such as schizophrenia (presence of delusions, hallucinations, mania and stupor) and severe depression especially in patients with suicidal tendencies. Recently, it has been reported that MECT has a certain effect in the treatment of severe paradoxical insomnia [5] . However, MECT on long-term refractory insomnia has not been reported. Recently, a long-term insomnia patient was admitted in our hospital and treated with MECT, which showed good response. We here report this case.
Case Report
Chief S2-P50/S1-P50 > 0.5 suggested the brain sensory gating (capacity of resisting disturbance) was missing and the brain cannot rule out irrelevant information.
EEG examination showed increased α waveform in front head. The main component of basic rhythm was the low amplitude α frequency waveform (9 -10 times/sec) combined with β frequency waveform (14 -28 times/sec) and the scattered θ waveform (4 -7 times/sec) with a poor amplitude modulation and no bilateral significant difference. 
Drug and TMS Therapy

MECT Treatment
The first MECT therapy was initiated on November 23, 2015, the therapy lasted 
Discussion
MECT is widely used in the treatment of severe schizophrenia [8] and depression [9] [10]. Less data indicate that MECT can be used in the treatment of insomnia. Insomnia is associated with feelings of restlessness, irritability, anxiety, and daytime fatigue and the symptoms resolve spontaneously after a few days or weeks [11] . However, chronic or refractory insomnia, lasting for three months or longer can reduce individual's function both socially and professionally. Insomnia is believed to be precursor and concurrent symptoms [12] of clinical depression [13] . The treatment of insomnia is an important step in complete alleviation of depression [14] .
MECT has achieved good effect in the treatment of severe paradoxical insomnia and depression. However, the patient with chronic insomnia in this case did not have typical symptoms of depression and she mainly suffered chronic insomnia accompanied by the symptoms of fear and slight anxiety. Although the patient has applied drug therapy or drug combined with TMS therapy, it is clear that these treatments had no significant effect on this intractable insomnia. Here, MECT therapy significantly improved sleep quality in a long-term intractable insomnia patient (from 2 hrs to 4 -5 hrs), thus ensuring the normal life of the patient with the ability to work. This has offered new important and effective clinical treatment for the patient with refractory insomnia. As a generally accepted therapy in wide field of psychiatric treatment, MECT is relatively safe and has a rapid action. To our knowledge, this is the first report to describe MECT application in a patient with chronic insomnia.
